Organigram Extends Innovation Investment with Phylos

Executive Summary

• Organigram Global Inc. announced a US$3 million top‑up to its existing loan to Phylos Bioscience, bringing the total loan principal to US$10 million, with maturity on May 25 2028.
• The amendment grants Organigram five‑year exclusive rights to selected autoflower cannabis genetics in multiple international markets and priority access to a pipeline of 30 new next‑generation seed cultivars delivered twice annually through 2030.
• The investment secures an enhanced seed‑based cultivation strategy, providing operational security, product differentiation and growth potential in both recreational and medical markets.

Key Details

• Financing: Additional US$3 million advance under amended loan agreement; combined principal now US$10 million; loan matures 25 May 2028; convertible or otherwise resolvable per amendment terms.
• Exclusive Rights: Five‑year exclusivity on Organigram’s chosen autoflower cultivars across Canada, Australia, the UK, Germany, Israel, with ability to add further territories.
• Seed Pipeline: Commitment to deliver 30 new next‑generation genetics twice a year through 2030, supporting both recreational and medical product lines.
• Strategic Benefit: Provides Organigram priority access to Phylos’ autoflower genetics pipeline, preferential economic terms, and long‑term international market rights, enhancing operational security and scalability of seed‑based cultivation.
• Quotes:
• Borna Zlamalik (SVP Innovation & International R&D, Organigram): Emphasized seed‑based cultivation as a key advantage delivering consistency, scalability and economic benefit.
• Ralph Risch (CEO, Phylos): Highlighted the investment’s role in accelerating development of new traits and F1 hybrid seeds, giving Organigram an economic edge.

Notable Quotes

• “Seed-based cultivation has become a key advantage of Organigram’s cultivation strategy, giving us unprecedented consistency, scalability, and economic benefit.” – Borna Zlamalik
• “Their investment allows Phylos to accelerate development of new traits and F1 hybrid seeds, while giving Organigram a meaningful economic advantage as the first to deploy those innovations at commercial scale.” – Ralph Risch